Amova Asset Management Americas Inc. Has $44.61 Million Position in Guardant Health, Inc. $GH

Amova Asset Management Americas Inc. lessened its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 24.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 483,557 shares of the company’s stock after selling 156,738 shares during the period. Amova Asset Management Americas Inc.’s holdings in Guardant Health were worth $44,608,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth $27,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Guardant Health during the fourth quarter worth about $31,000. Elyxium Wealth LLC acquired a new stake in Guardant Health during the fourth quarter worth about $35,000. Parallel Advisors LLC increased its holdings in Guardant Health by 164.7% in the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the period. Finally, EFG International AG bought a new position in Guardant Health in the 4th quarter valued at about $41,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Trading Down 5.0%

GH opened at $148.07 on Tuesday. The company’s 50 day moving average is $135.24 and its 200-day moving average is $110.66. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $174.08. The company has a market cap of $19.63 billion, a P/E ratio of -43.68 and a beta of 1.59.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Citigroup upped their price target on shares of Guardant Health from $150.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Sanford C. Bernstein lifted their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, July 2nd. Evercore restated an “outperform” rating and set a $200.00 price objective on shares of Guardant Health in a research report on Monday, July 6th. Mizuho upped their target price on Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Finally, Royal Bank Of Canada initiated coverage on Guardant Health in a report on Thursday, June 11th. They issued an “outperform” rating and a $185.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $160.04.

Insiders Place Their Bets

In other news, CEO Helmy Eltoukhy sold 100,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at approximately $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Meghan V. Joyce sold 10,000 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the transaction, the director owned 11,183 shares of the company’s stock, valued at $1,420,017.34. The trade was a 47.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 708,565 shares of company stock worth $90,556,597 over the last 90 days. Insiders own 5.60% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.